Latest Osteoarthritis Stories
MISSISSAUGA, ON, March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully...
Hundreds Will Urge Congress for More Arthritis Support in Person or through Virtual Summit on March 4-6 LOS ANGELES, Feb. 28, 2013 /PRNewswire-USNewswire/ -- Fourteen-year-old Jonathan Corthell of Henderson, NV will be traveling 2,400 miles to Washington, D.C. to ask Congress to support policies that will ensure more research, better treatments and greater access to care for those with arthritis, the nation's leading cause of disability. Corthell, who has suffered with Juvenile...
Three New Clinical Studies FREDERICK, Md., Feb. 28, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC PINK: BIEL), the maker of consumer medical devices for pain and healing, announces the initiation of a series of new clinical trials. Hernia Study: Dr. Frederik Berrevoetk, Current President of the Belgian Section of Abdominal Wall Surgery at the University Hospital Ghent, Belgium is conducting a postoperative recovery study on bilateral inguinal hernia repair. Hernia...
CHICAGO, Feb. 25, 2013 /PRNewswire/ -- Hokutou Holdings International Inc. (OTCPINK: HKTU) is pleased to announce today the planned addition of three supplement products to its product line. The Company recently completed a market analysis of specialty supplements for and has learned that seventy-eight percent of adults aged 55-plus use dietary supplements. Based on the market analysis, the Company has begun production of three products that are commonly used by older adults: Krill...
GREENWOOD VILLAGE, Colo., Feb. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it's Phase III clinical study of Ampion(TM) for the treatment for osteoarthritis of the knee will include a dose-escalation run-in( )study as recommended by the FDA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained "In the Australian trial, a single 4 ml dose provided promising...
A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis. The treatment improved pain and function, and in up to 73% of patients, appeared to delay the progression of osteoarthritis, which is a progressive disease. The study appears online, ahead of print, in the Clinical Journal of Sports Medicine. "This is a very positive study," said Brian Halpern, M.D., chief of the Primary Care...
SILVER SPRING, Nev., Feb. 13, 2013 /PRNewswire/ -- Geo Vision International Group Inc. (OTCPINK: GVIT), a nutraceutical and skinceutical company targeting Baby Boomers, announced today the release of its newest supplement product for joint repair. The Company's Glucosamine Sulfate supplement that was developed as part of its focus on health concerns for Baby Boomers and aging adults. Glucosamine Sulfate is a naturally occurring chemical found in the body in the fluid that is around...
FRANKFURT, Germany and LONDON, February 4, 2013 /PRNewswire/ -- The Federal Association of German Pharmacists (BVDA) today presented its "Innovation Award 2013" to FLEXISEQ(R), an innovative new treatment for pain and stiffness associated with osteoarthritis (OA). The BVDA president, and pharmacist Thomas Hieble, explained; "The jury awarded the prize to FLEXISEQ(R) in recognition of the application of its innovative Sequessome Technology(R) to deliver symptom relief to...
MISSISSAUGA, ON, Jan. 29, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX: NRI) announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a...
PERTH, Australia, Jan. 28, 2013 /PRNewswire/ -- Bone Medical Ltd (ASX: BNE), a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic(TM)( )peptide discovery technology. These first results confirm that BN006 reduces inflammation in a collagen-antibody induced arthritis disease model,...
